Lilly (LLY) Says Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and Effect of Lasmiditan in Patients with Prior Triptan Experience
May 8, 2019 6:54 AM
Eli Lilly and Company (NYSE: LLY) today announced new data and post-hoc analyses for lasmiditan, an investigational, oral, first-in-class ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
